Transdermal Nitroglycerin and Nifedipine in Preterm Labor
Managing Preterm Labor
About this trial
This is an interventional supportive care trial for Managing Preterm Labor
Eligibility Criteria
Inclusion Criteria:
- GA between 24 to 34 weeks
- early-onset signs of delivery (≥4 uterine contractions during 20 minutes, ≥1 centimeters (cm) of dilation and effacement over 80%).
Exclusion Criteria:
- maternal or fetal life-threatening conditions which require emergency termination
- multiple pregnancy
- premature rupture of membrane
- fatal anomaly or intra-uterine fetal death
- cervical dilation ≥4 cm
- any tocolytic treatment in previous days and positive allergy to GTN
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Group one have received Transdermal nitroglycerin
Group two have received nifedipine
transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below; One softgel every 20 min (4 doses) Two softgel every 6 hr (4 doses) One softgel every 6 hr (4 doses) One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied.